HRTX - Heron Therapeutics, Inc.
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD
Valuation measures4
| Market cap (intra-day) | 134.08M |
| Enterprise value | 230.99M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 1.11 |
| Price/book (mrq) | 12.60 |
| Enterprise value/revenue | 2.03 |
| Enterprise value/EBITDA | -1.57 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.92 |
| 52-week change 3 | -60.14% |
| S&P500 52-week change 3 | 2.72% |
| 52-week high 3 | 5.6200 |
| 52-week low 3 | 1.0700 |
| 50-day moving average 3 | 1.9756 |
| 200-day moving average 3 | 2.9253 |
Share statistics
| Avg vol (3-month) 3 | 2.58M |
| Avg vol (10-day) 3 | 2.23M |
| Shares outstanding 5 | 119.72M |
| Implied shares outstanding 6 | N/A |
| Float 8 | 98.86M |
| % held by insiders 1 | 0.31% |
| % held by institutions 1 | 102.54% |
| Shares short (14 May 2023) 4 | 21.65M |
| Short ratio (14 May 2023) 4 | 8.89 |
| Short % of float (14 May 2023) 4 | 21.67% |
| Short % of shares outstanding (14 May 2023) 4 | 18.09% |
| Shares short (prior month 13 Apr 2023) 4 | 23.19M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:20 |
| Last split date 3 | 12 Jan 2014 |
Financial highlights
Fiscal year
| Fiscal year ends | 30 Dec 2022 |
| Most-recent quarter (mrq) | 30 Mar 2023 |
Profitability
| Profit margin | -132.57% |
| Operating margin (ttm) | -122.46% |
Management effectiveness
| Return on assets (ttm) | -35.23% |
| Return on equity (ttm) | -2,408.88% |
Income statement
| Revenue (ttm) | 113.83M |
| Revenue per share (ttm) | 1.01 |
| Quarterly revenue growth (yoy) | 26.30% |
| Gross profit (ttm) | -50.51M |
| EBITDA | -136.51M |
| Net income avi to common (ttm) | -150.9M |
| Diluted EPS (ttm) | -1.3200 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 60.02M |
| Total cash per share (mrq) | 0.5 |
| Total debt (mrq) | 156.93M |
| Total debt/equity (mrq) | N/A |
| Current ratio (mrq) | 2.29 |
| Book value per share (mrq) | -0.10 |
Cash flow statement
| Operating cash flow (ttm) | -127.87M |
| Levered free cash flow (ttm) | -69.41M |
© 2023 Yahoo. All rights reserved.